With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?

With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?

CLICK HERE FOR CME CREDIT Back to Symposium

With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population? 

Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Peter Lio, MD

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois